RxDoctor Payments Data

Crystal Johnston Garcia, APRN

Adult Health · Lake Mary, FLNPI 1629796115

Payments from drug & device makers

$2,648in general payments, 2019–2025

Across 84 payments — averaging $31.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1000
  • Myriad Genetic Laboratories, Inc.$581
  • Johnson & Johnson$413
  • Endo Pharmaceuticals Inc.$119
  • Urogen Pharma, Inc.$111
  • Endo USA, Inc.$72
  • plus $352 from 10 others

What the payments were for

  • Travel & lodging$56321%
  • Food & beverage$2,00176%
  • Education$853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,648 in reported general payments places this provider in the 80th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$46,763
Medicare patients
242
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron62$45,836
MyrbetriqMirabegron41$29,118
Tamsulosin Hcl476$7,917
Estradiol30$1,737
Alfuzosin Hcl ErAlfuzosin Hcl53$1,490
Solifenacin Succinate25$1,171
Finasteride60$921
Testosterone Cypionate23$806
Anastrozole52$765
Cephalexin86$596
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$365
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen56$280
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim78$271
Dutasteride21$261
Doxycycline Hyclate13$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$72$45,83662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,237 adult health providers in Florida.

Other adult health in Lake Mary

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →